Gufic Biosciences quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	261	224	+16.6%
EBITDA	46.6	33.3	+40.0%
EBITDA margin	17.9%	14.9%	+3.0 pts
Profit before tax	30.0	17.3	+73.9%
Net profit	22.3	13.1	+70.7%
EPS	₹2.22	₹1.30	+70.8%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	261	252	231	237	224	205	208	204	203	195	202	215	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.5	−1.2	0.8	2.1	0.9	0.4	1.9	0.1	1.3	0.9	0.4	0.3
	261	251	232	239	225	205	210	204	204	196	202	215
	106	124	99.3	113	88.5	123	73.6	74.9	72.8	90.9	72.9	95.3
	14.0	8.9	15.8	25.7	14.3	10.8	15.5	16.6	12.4	14.3	12.0	15.7
	−5.2	−18.1	−14.1	−34.7	−2.0	−44.1	5.0	4.6	9.5	−16.7	10.4	−1.8
	41.8	38.1	40.1	37.5	36.0	35.6	34.0	28.5	29.0	29.6	30.6	26.8
	9.3	9.4	8.4	9.6	9.2	8.4	4.9	5.2	4.6	3.6	3.2	4.5
	7.7	7.6	7.7	7.8	7.7	7.8	4.6	4.3	4.3	4.3	4.1	4.3
	57.4	51.5	57.3	57.3	53.7	53.4	45.7	41.0	43.2	42.5	39.4	39.6
	231	222	214	217	207	195	183	175	176	169	173	184
	46.6	47.2	33.0	37.8	33.3	26.4	33.9	38.6	35.8	34.2	36.5	39.4
	38.9	39.6	25.3	30.1	25.6	18.5	29.3	34.3	31.5	29.9	32.3	35.1
Profit
	30.0	29.0	17.7	22.6	17.3	10.5	26.3	29.3	28.1	27.1	29.6	30.9
	30.0	29.0	17.7	22.6	17.3	10.5	26.3	29.3	28.1	27.1	29.6	30.9
	6.1	4.6	3.1	3.7	2.2	0.3	4.0	7.5	7.0	7.3	7.2	5.4
	1.6	2.4	2.2	2.0	2.0	2.5	3.0	−0.0	0.2	−0.2	0.1	2.4
	7.7	7.1	5.3	5.8	4.2	2.8	7.0	7.5	7.2	7.1	7.3	7.7
	22.3	21.9	12.4	16.8	13.1	7.7	19.3	21.8	20.9	20.0	22.3	23.2
	22.3	21.9	12.4	16.8	13.1	7.7	19.3	21.8	20.9	20.0	22.3	23.2
	0.1	0.5	0.0	0.0	0.0	−0.1	0.0	0.0	0.0	−0.4	0.0	0.0
	22.4	22.4	12.4	16.8	13.1	7.6	19.3	21.8	20.9	19.6	22.3	23.2
	—	21.9	12.4	16.8	13.1	7.7	19.3	21.8	20.9	—	—	—
	—	0.0	0.0	−0.0	0.0	0.0	−0.0	−0.0	−0.0	—	—	—
Per share
	₹2.22	₹2.18	₹1.24	₹1.68	₹1.30	₹0.77	₹1.93	₹2.17	₹2.08	₹2.00	₹2.23	₹2.39
	₹2.22	₹2.18	₹1.24	₹1.68	₹1.30	₹0.77	₹1.93	₹2.17	₹2.08	₹2.00	₹2.23	₹2.39
Other comprehensive income — detail
	0.1	0.5	—	—	0.0	−0.1	—	—	—	—	—	—
	—	0.7	—	—	—	−0.2	—	—	—	−0.5	—	—
	0.0	0.2	—	—	0.0	−0.0	—	—	—	—	—	—
	—	—	—	—	—	—	—	—	0.0	−0.1	—	—
	−0.1	0.0	—	—	0.0	0.0	—	—	—	—	—	—
	—	21.9	12.4	16.8	13.1	7.7	19.3	21.8	20.9	—	—	—
	—	0.0	0.0	−0.0	0.0	0.0	−0.0	−0.0	−0.0	—	—	—
Per share — as-filed variants
	₹2.22	₹2.18	₹1.24	₹1.68	₹1.30	₹0.77	₹1.93	₹2.17	₹2.08	₹2.00	₹2.23	₹2.39
	₹2.22	₹2.18	₹1.24	₹1.68	₹1.30	₹0.77	₹1.93	₹2.17	₹2.08	₹2.00	₹2.23	₹2.39
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	146	137	130	133	123	115	114	108	108	106	106	106
	55.9%	54.4%	56.3%	55.9%	55.0%	56.3%	54.7%	52.9%	53.3%	54.6%	52.8%	49.2%
Adjusted (ex-exceptional items) — derived
	30.0	29.0	17.7	22.6	17.3	10.5	26.3	29.3	28.1	27.1	29.6	30.9
	22.3	21.9	12.4	16.8	13.1	7.7	19.3	21.8	20.9	20.0	22.3	23.2
	₹2.22	₹2.18	₹1.24	₹1.68	₹1.30	₹0.77	₹1.93	₹2.17	₹2.08	₹2.00	₹2.23	₹2.39

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GUFICBIO₹423.75

Gufic Biosciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersRPGLIFE UNICHEMLAB GUJTHEM ORCHPHARMA SMSPHARMA INDSWFTLAB FDC IOLCPMcap ₹4,249 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	214.9	201.8	195.0	202.8	204.2	207.8	205.0	223.7	237.1	231.4	251.8	260.8
Other Income	0.3	0.4	0.9	1.3	0.1	1.9	0.4	0.9	2.1	0.8	-1.2	0.5
Total Income	215.2	202.2	195.9	204.1	204.3	209.7	205.4	224.6	239.2	232.2	250.6	261.3
Expenses
+ Cost of Materials Consumed	95.3	72.9	90.9	72.8	74.9	73.6	122.9	88.5	113.5	99.3	124.1	106.1
+ Purchases of Stock-in-Trade	15.7	12.0	14.3	12.4	16.6	15.5	10.8	14.3	25.7	15.8	8.9	14.0
+ Changes in Inventories	-1.8	10.4	-16.7	9.5	4.6	5.0	-44.1	-2.0	-34.7	-14.1	-18.1	-5.2
+ Employee Benefit Expense	26.8	30.6	29.6	29.0	28.5	34.0	35.6	36.0	37.5	40.1	38.1	41.8
+ Finance Costs	4.5	3.2	3.6	4.6	5.2	4.9	8.4	9.2	9.6	8.4	9.4	9.3
+ Depreciation & Amortisation	4.3	4.1	4.3	4.3	4.3	4.6	7.8	7.7	7.8	7.7	7.6	7.7
+ Other Expenses	39.6	39.4	42.5	43.2	41.0	45.7	53.4	53.7	57.3	57.3	51.5	57.4
Total Expenses	184.3	172.6	168.8	176.0	175.0	183.4	194.9	207.4	216.6	214.5	221.7	231.2
EBITDA	39.4	36.5	34.2	35.8	38.6	33.9	26.4	33.3	37.8	33.0	47.2	46.6
EBIT	35.1	32.3	29.9	31.5	34.3	29.3	18.5	25.6	30.1	25.3	39.6	38.9
Profit
PBT before Exceptional Items	30.9	29.6	27.1	28.1	29.3	26.3	10.5	17.3	22.6	17.7	29.0	30.0
Pretax Income	30.9	29.6	27.1	28.1	29.3	26.3	10.5	17.3	22.6	17.7	29.0	30.0
+ Current Tax	5.4	7.2	7.3	7.0	7.5	4.0	0.3	2.2	3.7	3.1	4.6	6.1
+ Deferred Tax	2.4	0.1	-0.2	0.2	-0.0	3.0	2.5	2.0	2.0	2.2	2.4	1.6
Tax Expense	7.7	7.3	7.1	7.2	7.5	7.0	2.8	4.2	5.8	5.3	7.1	7.7
Net Income	23.2	22.3	20.0	20.9	21.8	19.3	7.7	13.1	16.8	12.4	21.9	22.3
+ Net Income — Continuing Ops	23.2	22.3	20.0	20.9	21.8	19.3	7.7	13.1	16.8	12.4	21.9	22.3
+ Other Comprehensive Income	0.0	0.0	-0.4	0.0	0.0	0.0	-0.1	0.0	0.0	0.0	0.5	0.1
Total Comprehensive Income	23.2	22.3	19.6	20.9	21.8	19.3	7.6	13.1	16.8	12.4	22.4	22.4
Net Income to Common	—	—	—	20.9	21.8	19.3	7.7	13.1	16.8	12.4	21.9	—
Minority Interest	—	—	—	-0.0	-0.0	-0.0	0.0	0.0	-0.0	0.0	0.0	—
Per Share
Basic EPS	2.39	2.23	2.00	2.08	2.17	1.93	0.77	1.30	1.68	1.24	2.18	2.22
Diluted EPS	2.39	2.23	2.00	2.08	2.17	1.93	0.77	1.30	1.68	1.24	2.18	2.22
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-0.1	0.0	—	—	0.5	0.1
+ Items NOT to be Reclassified to P&L	—	—	-0.5	—	—	—	-0.2	—	—	—	0.7	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.0	0.0	—	—	0.2	0.0
+ Tax on Items NOT to be Reclassified — alt tag	—	—	-0.1	0.0	—	—	—	—	—	—	—	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	—	—	0.0	-0.1
Comprehensive Income — Owners of Parent	—	—	—	20.9	21.8	19.3	7.7	13.1	16.8	12.4	21.9	—
Comprehensive Income — Non-controlling Interests	—	—	—	-0.0	-0.0	-0.0	0.0	0.0	-0.0	0.0	0.0	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.39	2.23	2.00	2.08	2.17	1.93	0.77	1.30	1.68	1.24	2.18	2.22
Diluted EPS — Continuing Operations	2.39	2.23	2.00	2.08	2.17	1.93	0.77	1.30	1.68	1.24	2.18	2.22
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	105.8	106.4	106.4	108.1	108.1	113.6	115.4	123.0	132.6	130.4	136.9	145.8
Gross Margin %	49.22	52.75	54.55	53.29	52.92	54.68	56.26	54.96	55.94	56.35	54.35	55.91
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	30.9	29.6	27.1	28.1	29.3	26.3	10.5	17.3	22.6	17.7	29.0	30.0
Net Income Adj (tax-effected)	23.2	22.3	20.0	20.9	21.8	19.3	7.7	13.1	16.8	12.4	21.9	22.3
EPS Adj	2.39	2.23	2.00	2.08	2.17	1.93	0.77	1.30	1.68	1.24	2.18	2.22
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	9.7	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0	10.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Gufic Biosciences quarterly results

Gufic Biosciences (NSE: GUFICBIO) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹22.3 crore, up 70.7% from ₹13.1 crore in Q1 FY26 and up 1.9% from ₹21.9 crore in Q4 FY26. Revenue from operations was ₹261 crore, up 16.6% year on year and up 3.6% from the previous quarter.

Q2 FY26 results (a year earlier): 14 November 2025
Q1 FY27 results (the latest): 14 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹22.3 Cr+70.7% vs Q1 FY26+1.9% vs Q4 FY26
Q1 FY27 revenue: ₹261 Cr+16.6% vs Q1 FY26+3.6% vs Q4 FY26
Q1 FY27 operating margin: 14.9%+3.5 pts vs Q1 FY26−0.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹16.8 CrRevenue ₹237 Cr
Q1 FY27 EPS (basic): ₹2.22

Questions

When will Gufic Biosciences announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 14 November 2025.

What will Gufic Biosciences' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹16.8 crore and revenue from operations ₹237 crore. The latest quarter, Q1 FY27, had a net profit of ₹22.3 crore and revenue of ₹261 crore.

What were Gufic Biosciences' Q1 FY27 results?

Consolidated net profit was ₹22.3 crore, up 70.7% from ₹13.1 crore in Q1 FY26 and up 1.9% from ₹21.9 crore in Q4 FY26. Revenue from operations was ₹261 crore, up 16.6% year on year and up 3.6% from the previous quarter.

How has Gufic Biosciences' profit changed over the last four quarters?

Net profit by quarter: ₹16.8 crore in Q2 FY26, ₹12.4 crore in Q3 FY26, ₹21.9 crore in Q4 FY26 and ₹22.3 crore in Q1 FY27. That is ₹73.5 crore over the four quarters, up 18.7% from ₹61.9 crore in the four quarters before. Revenue from operations: ₹237 crore, ₹231 crore, ₹252 crore and ₹261 crore.

What was Gufic Biosciences' net profit in FY26?

Consolidated net profit was ₹64.2 crore in FY26 (April 2025–March 2026), down 7.8% from ₹69.6 crore in FY25. It was ₹86.1 crore in FY24.

What was Gufic Biosciences' revenue in FY26?

Revenue from operations was ₹944 crore in FY26 (April 2025–March 2026), up 15.2% from ₹820 crore in FY25. It was ₹807 crore in FY24.

Where do these Gufic Biosciences figures come from?

From Gufic Biosciences' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.